Milestone for Arana
Thursday, 02 October, 2008
Arana [ASX: ARA] has engineered an improved version of the VEGF-D antibody owned by Circadian Technologies [ASX: CIR] subsidiary Vegenics.
The antibody, designed to treat certain cancers, was modified into a humanised version using Arana's Superhumanisation technology.
It was then further refined using the company's EvoGene optimisation technology.
Conversion into humanised form will ensure that the risks of rejection of the treatment are minimised.
Circadian will shortly pay Arana milestone payments for the project, and Arana will be eligible to further milestone payments as the project advances through the various testing stages.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
